Related references
Note: Only part of the references are listed.Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential
Linlin Ma et al.
JOURNAL OF NANOBIOTECHNOLOGY (2020)
De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
Longxing Cao et al.
SCIENCE (2020)
Macrocyclic Peptide-Mediated Blockade of the CD47-SIRPα Interaction as a Potential Cancer Immunotherapy
Daisuke Hazama et al.
CELL CHEMICAL BIOLOGY (2020)
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
Branimir Sikic et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A novel human anti-AXL monoclonal antibody attenuates tumour cell migration
Yanting Duan et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2019)
Monoclonal anti-CD47 interference in red cell and platelet testing
Randall W. Velliquette et al.
TRANSFUSION (2019)
Selection and characterization of the novel anti-human PD-1 FV78 antibody from a targeted epitope mammalian cell-displayed antibody library
Longlong Luo et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
Cancer vaccines on the move
Jacques Banchereau et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy
Andre Veillette et al.
TRENDS IN IMMUNOLOGY (2018)
Programming CAR-T cells to kill cancer
Louai Labanieh et al.
NATURE BIOMEDICAL ENGINEERING (2018)
ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile
Steven E. Kauder et al.
PLOS ONE (2018)
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Ranjana Advani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Spotlight on protein N-terminal acetylation
Rasmus Ree et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
Penka S. Petrova et al.
CLINICAL CANCER RESEARCH (2017)
The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer
Hanke L. Matlung et al.
IMMUNOLOGICAL REVIEWS (2017)
New development in CAR-T cell therapy
Zhenguang Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Significance of CD47 expression in gastric cancer
Tomoya Sudo et al.
ONCOLOGY LETTERS (2017)
Resistance to PD1/PDL1 checkpoint inhibition
Jake S. O'Donnell et al.
CANCER TREATMENT REVIEWS (2017)
CD47 overexpression is associated with decreased neutrophil apoptosis/phagocytosis and poor prognosis in non-small-cell lung cancer patients
Lourdes Barrera et al.
BRITISH JOURNAL OF CANCER (2017)
Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis
Eunee Koh et al.
BIOMATERIALS (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Tumor-associated macrophages and anti-tumor therapies: complex links
Cristina Belgiovine et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
Kipp Weiskopf et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer
Sukhbir Kaur et al.
ONCOTARGET (2016)
Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma
Zhenyu Xiao et al.
CANCER LETTERS (2015)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
CD47 protein expression in acute myeloid leukemia: A tissue microarray-based analysis
Serena Galli et al.
LEUKEMIA RESEARCH (2015)
Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
Jie Liu et al.
PLOS ONE (2015)
CD47 and Osteopontin Expression in Diffuse Large B-cell Lymphoma With Nodal and Intravascular Involvement
Jason S. Starr et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Affinity maturation of antiHER2 monoclonal antibody MIL5 using an epitope-specific synthetic phage library by computational design
Chunxia Qiao et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2013)
Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
Kipp Weiskopf et al.
SCIENCE (2013)
Programmed cell removal: a new obstacle in the road to developing cancer
Mark P. Chao et al.
NATURE REVIEWS CANCER (2012)
An Ets2-Driven Transcriptional Program in Tumor-Associated Macrophages Promotes Tumor Metastasis
Tahera Zabuawala et al.
CANCER RESEARCH (2010)
Macrophage Diversity Enhances Tumor Progression and Metastasis
Bin-Zhi Qian et al.
CELL (2010)
Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47
Deborah Hatherley et al.
MOLECULAR CELL (2008)
The structure of the macrophage signal regulatory protein α (SIRPα) inhibitory receptor reveals a binding face reminiscent of that used by T cell receptors
Deborah Hatherley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The SIRP family of receptors and immune regulation
AN Barclay et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Share Paper
